Dauch (DCH) Q2 2026 Earnings Call Transcript

Dauch Corporation (NYSE: DCH) reported Q2 2026 sales of $2.96B (+92% YoY from $1.54B) and adjusted EBITDA of $389.6M (13.2% margin), with Dowlais contributing about $1.45B of sales and ~$180M of EBITDA. Management raised full-year sales guidance to $10.6B–$10.8B and increased low-end adjusted EBITDA to $1.36B–$1.425B, citing first-half performance and integration progress; synergy run-rate reached $70M within five months toward a $300M 3-year target. Balance-sheet actions included voluntary redemption of 6.875% notes, totaling $250M during the period and leaving no major maturities until 2029, with net leverage at 2.6x as of June 30, 2026.

Analysis

The setup is better than the headline numbers imply: this is now a deleveraging-and-integration story with optionality from a cleaner global footprint, not just a cyclical auto supplier. The market should reward the combination if management keeps converting visible SG&A wins into procurement/operating leverage; those latter buckets matter more because they are stickier and can support a higher midcycle margin by 2027 rather than only a one-quarter beat.

Near term, the biggest risk is that the September GM launch creates an air pocket just as investor expectations are rising. That makes the next 4-8 weeks more about volume noise than fundamentals, and any launch hiccup would likely compress the multiple before the synergy narrative can reassert itself. The real falsifier is not a softer quarter in isolation, but a failure to keep free cash flow and leverage moving toward the sub-2.5x target while restructuring cash costs remain elevated into 2027.

The contrarian miss is that the market may be underestimating how much of the quoting pipeline is now aligned with the company’s most profitable mix: ICE/hybrid, trucks, and localization. If tariff pressure pushes OEMs to re-source, DCH is better positioned than cleaner-technology or Europe-only peers to capture that work, while the lagged benefit could show up in 2027 awards rather than 2026 revenue. Conversely, if energy/freight inflation stays sticky and GM production normalizes more slowly than expected, the synergy story can still be right while equity performance disappoints on timing.

Key Decisions for Investors

• Accumulate DCH on weakness over the next 2-6 weeks, with the thesis that the September GM changeover creates a temporary tape break before the Nov. 17 capital markets day can re-rate the stock.
• Use a pair trade: long DCH / short CVGI for 1-3 months, betting that DCH’s mix, scale and integration savings outperform a lower-quality supplier exposed to the same auto-cycle but with less balance-sheet flexibility.
• Do not chase the post-earnings move; wait for any pullback tied to launch-downtime headlines, then add only if management reiterates >$100M run-rate synergies and 2026 FCF remains within guidance.
• If DCH leverage fails to move clearly below 2.5x by mid-2027 or if restructuring cash does not fall meaningfully, cut the position; that would imply the equity is becoming a balance-sheet story without balance-sheet improvement.
• Watch GM and the North American truck production cadence as the key catalyst chain; if launch disruption is limited and awards convert, DCH can work as a 6-12 month re-rating trade rather than a short-term momentum name.